Oct 14, 2024
In this episode, Dr. Valentin Fuster summarizes the pivotal October 2024 issue of the JACC Journal, focusing on the intersection of obesity and cardiology. Key discussions include the revolutionary impact of anti-obesity medications like semaglutide on heart health, the intricate relationship between obesity and heart...
Oct 14, 2024
In the October 22, 2024 issue of JACC, a podcast explores the promising benefits of semaglutide, a glucagon-like peptide receptor agonist, in treating obesity-related heart failure. The episode discusses key findings from original research, highlighting how semaglutide improves cardiac structure and function,...
Oct 14, 2024
In this episode, Dr. Valentin Foster highlights the October 2024 issue of JACC, which delves into the benefits of semaglutide for obesity-related heart failure with preserved ejection fraction. A key study presented shows that semaglutide significantly improves heart failure symptoms and physical limitations,...
Oct 14, 2024
In this episode, Dr. Valentin Foster explores the October issue of JACC, which highlights obesity and the potential benefits of glucagon-like peptide receptor agonists, particularly semaglutide, in treating heart failure. He delves into the FLOW trial, revealing how semaglutide significantly reduced heart failure events...
Oct 14, 2024
In this episode, Dr. Valentin Foster explores the October 2024 issue of JACC, highlighting the significant benefits of semaglutide, particularly for individuals with obesity and cardiovascular disease. He focuses on findings from the SELECT trial, which demonstrate that semaglutide reduces overall and cardiovascular...